IQVIA and Veeva Systems, both publicly traded on the NYSE under the symbols IQV and VEEV, have announced the formation of global partnerships across their clinical and commercial operations. Alongside these new agreements, the companies have resolved all previously pending legal disputes. This long-term collaboration is set to improve efficiency by allowing customers to use both companies’ technologies, software, services, and data together without added complexity.
Health Technology Insights: Saigon Technology Powers AI Beyond SaaS Limits
The partnership is designed to simplify how clients in the life sciences and healthcare sectors interact with both platforms across areas such as sales, marketing, clinical research, and data management. In the commercial segment, the agreement includes mutual third-party access rights. This allows IQVIA data to be used within Veeva’s tools like Veeva Network for master data management, Veeva Nitro for analytics, and Veeva AI. Similarly, Veeva data can now integrate with IQVIA’s commercial offerings. IQVIA has also joined several of Veeva’s partner programs to help ensure better compatibility and faster project execution.
From a clinical standpoint, IQVIA has joined Veeva’s CRO Clinical Data Partner program, enabling the company to run clinical trials using Veeva’s software, including the setup of electronic data capture (EDC) systems. By combining IQVIA’s clinical expertise with Veeva’s digital tools, the collaboration is expected to improve study timelines, including faster database builds and more efficient data delivery.
Health Technology Insights: Angle Health and PerfectQuote Launch Real-Time Rate Quotes
Peter Gassner, founder and CEO of Veeva, said, “We are committed to supporting seamless product and service integration with IQVIA for the benefit of our joint customers and the industry as a whole. I’m excited about the potential for our clinical and commercial partnerships to create significant value for our shared customers.”
Ari Bousbib, chairman and CEO of IQVIA, also shared his thoughts on the collaboration: “IQVIA and Veeva’s partnerships bring together best-in-class capabilities in information, AI, technology, and services for our shared clients. This will enable IQVIA customers using Veeva platforms to accelerate clinical development, bring treatments to market more efficiently, and improve access to innovations for patients.”
Overall, this marks a significant shift in the relationship between IQVIA and Veeva. Clients now benefit from the combined capabilities of two leading healthcare and life sciences technology providers, with fewer integration issues and no legal barriers moving forward. The collaboration aims to deliver more value through improved interoperability and faster access to innovation.
Health Technology Insights: Dried Plasma Innovation Addresses Critical Global Need
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
